Jubilant Pharmova share price
NSE: JUBLPHARMABSE: 530019Pharmaceuticals & BiotechnologySmall Cap
Jubilant Pharmova Limited · Formerly Jubilant Life Sciences · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jun 1981 on BSE, Jun 2003 on NSE
Last close ₹943.90down ₹15.90 (1.66%)BSE ₹945.35
Share price at the NSE close on 28 Oct 2026. Previous close ₹959.80.
28 Oct: open ₹953.30, high ₹959.80, low ₹936.40
52-week range of traded prices to 28 Oct 2026
₹786.05Low, 9 Mar 2026₹1,183.00High, 4 Nov 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹15,035 Cr422nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 42.70
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹59 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 36.55
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.12
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.53%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 5.3%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹59 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 6.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 7.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.45
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 57,06841.5% delivered
Results
Consolidated; ₹ crore.Jubilant Pharmova quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +16.3%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- −23.5%
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹2,229 Crdown 2.65%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹56 Crdown 52.72%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 2.5%
Revenue by quarter
Peak revenue ₹2,290 Cr, quarter to Mar 2026; lowest ₹1,752 Cr, quarter to Sep 2024
Net profit by quarter, a loss in red
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,752 | 1,822 | 1,929 | 1,901 | 1,966 | 2,123 | 2,290 | 2,229 |
| Net profit | 103 | 101 | 151 | 103 | 120 | 56 | 119 | 56 |
| Net margin | 5.8% | 5.5% | 7.8% | 5.4% | 6.1% | 2.6% | 5.2% | 2.5% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹8,280 Crup 14.45%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹398 Crdown 52.47%
- Net margin
- 4.8%
Revenue by year
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 1 of the 10 years shown
The years either side of a change of basis do not compare. From the year to Mar 2021, the company's revenue for that year, ₹6,099 Cr, differs from its quarters added, ₹7,619 Cr; the company reports the part of the business demerged on 4 Feb 2021 as discontinued, and figures before the change include it.
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6,006 | 7,558 | 9,111 | 9,154 | 6,099 | 6,059 | 6,282 | 6,703 | 7,235 | 8,280 |
| Net profit | 576 | 634 | 577 | 898 | 836 | 413 | −65 | 73 | 836 | 398 |
| Net margin | 9.6% | 8.4% | 6.3% | 9.8% | – | 6.8% | −1.0% | 1.1% | 11.6% | 4.8% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share. Net margin is left blank for Mar 2021: the profit includes the result of a business the company has discontinued, which the revenue does not, so the two make no margin.
Business segments
Share of revenue, year to Mar 2026, consolidated.Segment revenue and profit
- RadiopharmaRadiopharma, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹3,690 Crup 8.92%44.3%
- Contract Development and Manufacturing Organisation - Sterile InjectablesContract Development and Manufacturing Organisation - Sterile Injectables, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹1,813 Crup 34.00%21.7%
- Contract Research, Development and Manufacturing OrganisationContract Research, Development and Manufacturing Organisation, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹1,265 Crup 7.85%15.2%
- Allergy ImmunotherapyAllergy Immunotherapy, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹796 Crup 11.41%9.5%
- GenericsGenerics, share of revenue. The segment's revenue as a percentage of the revenue of all the company's reported business segments together, leaving out eliminations between them and unallocated items.₹774 Crup 12.87%9.3%
The pill is the change in revenue on the year before; the share is of all the businesses together.
Valuation
Today, against the company's own history. Its history crosses a change of basis in the accounts in the year to Mar 2021: days before it are of the company before the change.Jubilant Pharmova PE ratio and valuation
Price to earnings
At or below today's level on 57% of 926 trading days over the last 5 years.
LowestHighest
Its median35.45Industry median28.10
Price to book
At or below today's level on 57% of 1,906 trading days since Oct 2018.
LowestHighest
Its median2.00Industry median2.99
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 45% of 2,457 trading days over the last 10 years.
LowestHighest
Its median0.56%Industry median0.48%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −8.3% | −52.5% | +92.0% | 0.6% |
| 3 years | +43.7% | – | – | 0.7% |
| 5 years | +4.7% | −13.7% | +20.1% | 1.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record. Earnings growth over 1 and 5 years includes one-off items (exceptional items and the result of businesses sold or closed) of more than a tenth of the profit of the years to Mar 2021, Mar 2025 and Mar 2026.
Mutual fund holdings
35 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 11 of the 21 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.All 35 funds holding Jubilant Pharmova
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 2
- AddedAdded. Funds that held more shares than at the end of the month before.
- 9
- CutCut. Funds that held fewer shares than at the end of the month before.
- 12
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 12
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end. Sold out in the glossary
- 34
| Fund | |||
|---|---|---|---|
 Bandhan Small Cap FundBandhan Mutual Fund | 48,72,987 | 1.40% | ₹501.3 Cr |
 quant Small Cap Fundquant Mutual Fund | 29,47,185 | 0.85% | ₹303.2 Cr |
 Kotak Multi Cap FundKotak Mahindra Mutual Fund | 18,28,846 | 0.62% | ₹188.2 Cr |
| Bandhan Focused FundBandhan Mutual Fund | 12,61,984 | 6.22% | ₹129.8 Cr |
 Abakkus Flexi Cap FundAbakkus Mutual Fund | 6,13,923 | 0.81% | ₹63.2 Cr |
 Aditya Birla Sun Life Small Cap FundAditya Birla Sun Life Mutual Fund | 5,00,687 | 0.84% | ₹51.5 Cr |
 HDFC Manufacturing fundHDFC Mutual Fund | 5,00,000 | 0.50% | ₹51.4 Cr |
| Abakkus Small Cap FundAbakkus Mutual Fund | 4,69,188 | 1.49% | ₹48.3 Cr |
| HDFC Pharma and Healthcare FundHDFC Mutual Fund | 3,17,568 | 0.93% | ₹32.7 Cr |
| Kotak Special Opportunities FundKotak Mahindra Mutual Fund | 2,85,765 | 1.53% | ₹29.4 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 28 Oct 2025.Jubilant Pharmova insider trading
No promoter, director, key manager or employee bought or sold on the market.
- Promoters and promoter group: no market trade · 2 pledge filings of unclear kind
- Others: no market trade · 1 off-market move
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Jubilant Pharmova competitors and peers
Pharmaceuticals, 215 listed companies, priced on 28 Oct 2026. The table lists the 8 companies closest to Jubilant Pharmova in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Eris LifesciencesERIS | 16,307 | 23.05 | 3.93 | +11.1% | +70.2% | 19.6% | 13.4% | 0.61% |
 AstraZeneca Pharma IndiaASTRAZEN | 15,593 | 91.93 | 17.87 | +31.1% | −7.5% | 20.6% | 24.4% | 0.58% |
 Natco PharmaNATCOPHARM | 15,556 | 13.59 | – | −20.7% | −32.6% | 13.6% | 8.6% | 0.57% |
 Alembic PharmaceuticalsAPLLTD | 15,387 | 22.26 | 2.71 | +14.1% | +14.6% | 12.7% | 11.8% | 1.53% |
 Marksans PharmaMARKSANS | 13,831 | 26.76 | 4.57 | – | – | 17.1% | 19.9% | 0.29% |
 CORONA RemediesCORONA | 13,459 | 67.62 | 18.02 | – | – | 26.6% | 30.9% | 0.45% |
 Concord BiotechCONCORDBIO | 13,271 | 46.98 | 6.39 | +4.0% | −12.8% | 14.5% | 15.9% | 0.60% |
 Akums Drugs and PharmaceuticalsAKUMS | 11,375 | 38.99 | 3.43 | +9.2% | −14.6% | 9.2% | 12.0% | 0.42% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Jubilant Pharmova dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹5.00 a share, in 7 years, the latest the year to Mar 2026.
| Ex-date | Type | Per share |
|---|---|---|
| 24 Jul 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹5.00 |
| 25 Jul 2025 | Final | ₹5.00 |
| 2 Aug 2024 | Final | ₹5.00 |
| 10 Aug 2023 | Final | ₹5.00 |
| 11 Aug 2022 | Final | ₹5.00 |
| 5 Aug 2021 | Final | ₹5.00 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Jubilant Pharmova announcements
Oct 2026
21 Oct · Meeting
21 Oct · Rating
14 Oct · Rating
8 Oct
Jubilant Pharmova share price by year
Each calendar year to 2025.Jubilant Pharmova share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 1,073.30 | −2.9% | 1,236.30 | 828.10 |
| 2024 | 1,105.20 | +102.6% | 1,262.60 | 535.25 |
| 2023 | 545.45 | +45.6% | 545.45 | 271.85 |
| 2022 | 374.75 | −36.1% | 590.15 | 313.30 |
| 2021Demerger | 586.60 | −30.6% | 1,025.60 | 558.40 |
| 2020 | 844.90 | +57.3% | 874.70 | 234.35 |
| 2019 | 537.00 | −24.4% | 873.50 | 401.80 |
| 2018 | 710.60 | −9.9% | 1,007.40 | 647.20 |
| 2017 | 788.30 | +24.7% | 853.45 | 603.90 |
| 2016 | 632.20 | +53.7% | 709.95 | 288.40 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. With the demerger of 4 Feb 2021 reinvested, the change in 2021 is −20.0%.
Recent sessions
The 9 trading days to 27 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 27 Oct 2026 | 939.80 | 965.90 | 931.40 | 959.80 | 952.09 | 1,43,473 | 53.0% |
| 26 Oct 2026 | 938.30 | 941.30 | 918.00 | 937.00 | 930.70 | 81,042 | 29.3% |
| 23 Oct 2026 | 932.00 | 944.80 | 895.10 | 938.30 | 919.49 | 1,42,183 | 42.9% |
| 22 Oct 2026 | 928.00 | 944.80 | 913.00 | 932.20 | 930.69 | 1,07,635 | 45.3% |
| 21 Oct 2026 | 938.20 | 938.50 | 911.60 | 929.40 | 924.04 | 1,77,629 | 48.5% |
| 19 Oct 2026 | 931.60 | 948.40 | 931.50 | 935.80 | 941.59 | 80,672 | 55.0% |
| 16 Oct 2026 | 938.20 | 954.90 | 928.60 | 938.60 | 944.87 | 1,34,966 | 53.4% |
| 15 Oct 2026 | 939.90 | 949.00 | 919.70 | 938.20 | 936.42 | 2,08,268 | 46.5% |
| 14 Oct 2026 | 945.00 | 948.90 | 928.50 | 938.90 | 938.07 | 3,91,864 | 53.0% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Demerger history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 4 Feb 2021 | Demerger | 0.8678 | Part of the business became a separate company. The factor is the opening price on the ex-date divided by the previous close. The chart shows earlier prices with the demerger reinvested. |
| 25 Nov 2010 | Demerger | 0.9893 | Part of the business became a separate company. The factor is the opening price on the ex-date divided by the previous close. The chart shows earlier prices with the demerger reinvested. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout.
Company details
- NSE symbol
- JUBLPHARMA
- BSE code
- 530019
- ISIN
- INE700A01033
- Industry
- Pharmaceuticals & Biotechnology
- Former symbols
- JUBILANT, VAMORGANIC
- Website
- www.jubl.com
- CIN
- L24116UP1978PLC004624
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1978
- Registered office
- Bhartiagram, Gajraula, Jyotiba Phoolay Nagar, Bhartigram 244223, Uttar Pradesh
- Share registrar
- Alankit Assignments Ltd
- Keeps the register of shareholders and handles transfers and dividend payments